Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 126

1.

Psoriatic arthritis and obesity: the role of anti-IL-12/IL-23 treatment.

Costa L, Ramonda R, Ortolan A, Favero M, Foti R, Visalli E, Rossato M, Cacciapaglia F, Lapadula G, Scarpa R.

Clin Rheumatol. 2019 Sep;38(9):2355-2362. doi: 10.1007/s10067-019-04663-6. Epub 2019 Jun 28.

PMID:
31264033
2.

Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis.

Becker M, Graf N, Sauter R, Allanore Y, Curram J, Denton CP, Khanna D, Matucci-Cerinic M, de Oliveira Pena J, Pope JE, Distler O; EUSTAR Collaborators; EUSTAR Collaborators (numerical order of centres).

Ann Rheum Dis. 2019 Sep;78(9):1242-1248. doi: 10.1136/annrheumdis-2019-215145. Epub 2019 Jun 21.

3.

Body mass index as a driver of selection of biologic therapy in rheumatoid arthritis. Results from the US-CLARA study.

Di Carlo M, Salaffi F, Gremese E, Iannone F, Lapadula G, Ferraccioli G; GISEA Study Group.

Eur J Intern Med. 2019 Aug;66:57-61. doi: 10.1016/j.ejim.2019.05.017. Epub 2019 May 18.

PMID:
31113709
4.

Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey.

Lopalco G, Venerito V, Cantarini L, Emmi G, Salaffi F, Di Carlo M, Tafuri S, Gentileschi S, Di Scala G, Nivuori M, Cacciapaglia F, Galeazzi M, Lapadula G, Iannone F.

Clin Exp Rheumatol. 2019 Sep-Oct;37(5):762-767. Epub 2019 Apr 16.

PMID:
31025925
5.

Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response.

Vitale A, Cavalli G, Colafrancesco S, Priori R, Valesini G, Argolini LM, Baldissera E, Bartoloni E, Cammelli D, Canestrari G, Sota J, Cavallaro E, Massaro MG, Ruscitti P, Cipriani P, De Marchi G, De Vita S, Emmi G, Ferraccioli G, Frassi M, Gerli R, Gremese E, Iannone F, Lapadula G, Lopalco G, Manna R, Mathieu A, Montecucco C, Mosca M, Piazza I, Piga M, Pontikaki I, Romano M, Rossi S, Rossini M, Silvestri E, Stagnaro C, Talarico R, Tincani A, Viapiana O, Vitiello G, Galozzi P, Sfriso P, Gaggiano C, Rigante D, Dagna L, Giacomelli R, Cantarini L.

Front Pharmacol. 2019 Apr 2;10:296. doi: 10.3389/fphar.2019.00296. eCollection 2019.

6.

Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis.

Sobanski V, Giovannelli J, Allanore Y, Riemekasten G, Airò P, Vettori S, Cozzi F, Distler O, Matucci-Cerinic M, Denton C, Launay D, Hachulla E; EUSTAR Collaborators.

Arthritis Rheumatol. 2019 Sep;71(9):1553-1570. doi: 10.1002/art.40906. Epub 2019 Aug 12.

PMID:
30969034
7.

Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study.

Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ, Truchetet ME, Braun-Moscovici Y, Iannone F, Novikov PI, Lescoat A, Siegert E, Castellví I, Airó P, Vettori S, De Langhe E, Hachulla E, Erler A, Ananieva L, Krusche M, López-Longo FJ, Distler JHW, Hunzelmann N, Hoffmann-Vold AM, Riccieri V, Hsu VM, Pozzi MR, Ancuta C, Rosato E, Mihai C, Kuwana M, Saketkoo LA, Chizzolini C, Hesselstrand R, Ullman S, Yavuz S, Rednic S, Caimmi C, Bloch-Queyrat C, Allanore Y; for EUSTAR network.

Ann Rheum Dis. 2019 Jul;78(7):979-987. doi: 10.1136/annrheumdis-2018-214816. Epub 2019 Apr 9.

PMID:
30967395
8.

Effectiveness of Certolizumab-Pegol in Rheumatoid Arthritis, Spondyloarthritis, and Psoriatic Arthritis Based on the BIOPURE Registry: Can Early Response Predict Late Outcomes?

Iannone F, Semeraro A, Carlino G, Santo L, Bucci R, Quarta L, Maruotti N, Zuccaro C, Marsico A, Falappone PCF, Mazzotta D, Cantatore FP, Muratore M, Lapadula G.

Clin Drug Investig. 2019 Jun;39(6):565-575. doi: 10.1007/s40261-019-00782-9.

PMID:
30941736
9.

Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort.

Wu W, Jordan S, Graf N, de Oliveira Pena J, Curram J, Allanore Y, Matucci-Cerinic M, Pope JE, Denton CP, Khanna D, Distler O; EUSTAR Collaborators.

Ann Rheum Dis. 2019 May;78(5):648-656. doi: 10.1136/annrheumdis-2018-213455. Epub 2019 Mar 9.

10.

Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA.

Atzeni F, Sarzi-Puttini P, Sebastiani M, Panetta V, Salaffi F, Iannone F, Carletto A, Foti R, Gremese E, Govoni M, Marchesoni A, Favalli E, Gorla R, Ramonda R, Ferraccioli G, Lapadula G; GISEA group.

Clin Exp Rheumatol. 2019 Jul-Aug;37(4):649-655. Epub 2019 Feb 11.

PMID:
30767865
11.

Epidemiological profile of non-infectious uveitis from the rheumatologist's perspective: a survey from two tertiary referral centres in Italy.

Lopalco G, Venerito V, Sota J, Rigante D, Guerriero S, Orlando I, Franceschini R, Favale R, Lapadula G, Castelli B, Frediani B, Galeazzi M, La Torre F, Iannone F, Tosi GM, Fabiani C, Cantarini L.

Clin Exp Rheumatol. 2018 Nov-Dec;36(6 Suppl 115):68-73. Epub 2018 Dec 12.

PMID:
30582503
12.

Italian consensus recommendations for the management of hepatitis C infection in patients with rheumatoid arthritis.

Sebastiani M, Milazzo L, Atzeni F, Vacchi C, Manfredi A, Quartuccio L, Scirè C, Gaeta GB, Lapadula G, Armignacco O, Tavio M, D'Angelo S, Meroni P, Bazzichi L, Grassi W, Mathieu A, Mastroianni C, Sagnelli E, Santantonio T, Foppa CU, Puoti M, Sarmati L, Airò P, Epis OM, Scrivo R, Gargiulo M, Riva A, Ciancio G, Zehender G, Taliani G, Meroni L, Sollima S, Sarzi-Puttini P, Galli M.

Mod Rheumatol. 2019 Jan 22:1-8. doi: 10.1080/14397595.2018.1558918. [Epub ahead of print] Erratum in: Mod Rheumatol. 2019 Apr 2;:1.

PMID:
30582388
13.

Red flags for appropriate referral to the gastroenterologist and the rheumatologist of patients with inflammatory bowel disease and spondyloarthritis.

Felice C, Leccese P, Scudeller L, Lubrano E, Cantini F, Castiglione F, Gionchetti P, Orlando A, Salvarani C, Scarpa R, Vecchi M, Olivieri I, Armuzzi A; Italian SpA-IBD Expert Panel Group.

Clin Exp Immunol. 2019 Apr;196(1):123-138. doi: 10.1111/cei.13246. Epub 2019 Jan 9.

PMID:
30554407
14.

Sarcopenia in Patients with Rheumatic Diseases: Prevalence and Associated Risk Factors.

Barone M, Viggiani MT, Anelli MG, Fanizzi R, Lorusso O, Lopalco G, Cantarini L, Di Leo A, Lapadula G, Iannone F.

J Clin Med. 2018 Dec 1;7(12). pii: E504. doi: 10.3390/jcm7120504.

15.

Patients', physicians', nurses', and pharmacists' preferences on the characteristics of biologic agents used in the treatment of rheumatic diseases.

Scalone L, Sarzi-Puttini P, Sinigaglia L, Montecucco C, Giacomelli R, Lapadula G, Olivieri I, Giardino AM, Cortesi PA, Mantovani LG, Mecchia M.

Patient Prefer Adherence. 2018 Oct 16;12:2153-2168. doi: 10.2147/PPA.S168458. eCollection 2018.

16.

Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment.

Cacciapaglia F, Anelli MG, Rinaldi A, Fornaro M, Lopalco G, Scioscia C, Lapadula G, Iannone F.

Mediators Inflamm. 2018 Oct 14;2018:2453265. doi: 10.1155/2018/2453265. eCollection 2018.

17.

The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts.

Favalli EG, Becciolini A, Caporali R, Todoerti M, Iannone F, Dinoia L, Sebastiani M, Spinella A, Gremese E, Cianci F, Atzeni F, Bandinelli F, Ferraccioli G, Lapadula G; GISEA Study Group.

Autoimmun Rev. 2018 Dec;17(12):1251-1258. doi: 10.1016/j.autrev.2018.07.002. Epub 2018 Oct 16. Review.

PMID:
30339886
18.

Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus.

Todoerti M, Favalli EG, Iannone F, Olivieri I, Benucci M, Cauli A, Mathieu A, Santo L, Minisola G, Lapadula G, Bucci R, Gremese E, Caporali R.

Rheumatology (Oxford). 2018 Oct 1;57(57 Suppl 7):vii42-vii53. doi: 10.1093/rheumatology/key195. Review.

PMID:
30289539
19.

Correction to: Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet's disease.

Vitale A, Emmi G, Lopalco G, Fabiani C, Gentileschi S, Silvestri E, Di Scala G, Iannone F, Frediani B, Galeazzi M, Lapadula G, Rigante D, Cantarini L.

Clin Rheumatol. 2019 Jan;38(1):267. doi: 10.1007/s10067-018-4302-0.

PMID:
30242638
20.

Prompt Clinical Response to Secukinumab in Patients with Axial Spondyloarthritis: Real Life Observational Data from Three Italian Referral Centers.

Gentileschi S, Vitale A, Rigante D, Lopalco G, Emmi G, Orlando I, Di Scala G, Sota J, Fabiani C, Frediani B, Galeazzi M, Lapadula G, Iannone F, Cantarini L.

Isr Med Assoc J. 2018 Jul;20(7):438-441.

Supplemental Content

Loading ...
Support Center